Zobrazeno 1 - 10
of 104
pro vyhledávání: '"Marian Loffredo"'
Publikováno v:
Prostate Cancer, Vol 2014 (2014)
Purpose. We investigated whether NS-RP increased risk of PSA failure and whether PSA should be included as a selection criterion for NS. Methods. We evaluated 357 consecutive men with screen-detected PC who underwent open RP without adjuvant radiothe
Externí odkaz:
https://doaj.org/article/0c0e985a46154f21b18d8cefb807f603
Publikováno v:
Prostate Cancer, Vol 2014 (2014)
Background. Increasing body mass index (BMI) is associated with increased risk of mortality; however, quantifying weight gain in men undergoing androgen deprivation therapy (ADT) for prostate cancer (PC) remains unexplored. Methods. Between 1995 and
Externí odkaz:
https://doaj.org/article/0a39f8b7195b466aba14a66d643d01a4
Publikováno v:
Prostate Cancer, Vol 2014 (2014)
Purpose. Increasing body mass index (BMI) is associated with higher risk prostate cancer (PC) at presentation. Whether increasing BMI also prompts earlier salvage androgen suppression therapy (sAST) is unknown. Materials and Methods. Between 1995 and
Externí odkaz:
https://doaj.org/article/bf93c108521749fb9206019fb79379b0
Autor:
Rolf Freter, Elizabeth McMahon, Anthony V. D'Amico, Molly Sullivan, Parvesh Kumar, Jeffrey Y.C. Wong, Glenn J. Bubley, Shana Medeiros, W. Jeffrey Baker, Juan Carlos Vera, David Joseph, Philip W. Kantoff, Wanling Xie, Marian Loffredo, James W. Denham, Richard Hellwig, Andrew A. Renshaw
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 39(26)
PURPOSEAlthough docetaxel is not recommended when managing men with unfavorable-risk prostate cancer (PC) given negative or inconclusive results from previous randomized trials, unstudied benefits may exist.METHODSBetween September 21, 2005, and Janu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62b455348068e62403ae18b9bd22e189
https://pubmed.ncbi.nlm.nih.gov/34534000
https://pubmed.ncbi.nlm.nih.gov/34534000
Autor:
Luke R.G. Pike, Anthony V. D'Amico, Philip W. Kantoff, Ming-Hui Chen, Jing Wu, Marian Loffredo, John Pfail, Andrew A. Renshaw
Publikováno v:
Urology. 126:145-151
Objective To assess whether the time to prostate-specific antigen (PSA) nadir (TTN) has differential prognostic value in men who reach an undetectable vs detectable PSA nadir. Methods Two hundred and four men from a prospective randomized controlled
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a312d3809aba09051d2c8aaaae3cd0f5
https://doi.org/10.1016/j.urology.2018.11.056
https://doi.org/10.1016/j.urology.2018.11.056
Autor:
Eric J. Small, Andrew A. Renshaw, Danielle S. Bitterman, Jing Wu, Philip W. Kantoff, Ming-Hui Chen, Anthony V. D'Amico, Marian Loffredo
Publikováno v:
Cancer
BACKGROUND Although both PSA nadir (PSAn) and testosterone levels at PSA failure are known prognostic factors in men undergoing radiation therapy (RT) and androgen deprivation therapy (ADT) for unfavorable-risk prostate cancer (PC), it is unclear whe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::992ab831cb355cd189c7f7bf8d712e15
https://pubmed.ncbi.nlm.nih.gov/33823065
https://pubmed.ncbi.nlm.nih.gov/33823065
Autor:
Andrew A. Renshaw, Marian Loffredo, Susan G.R. McDuff, Anthony V. D'Amico, Ming-Hui Chen, Philip W. Kantoff
Publikováno v:
Cancer. 124:1391-1399
BACKGROUND Herein, the authors evaluated how the time to testosterone rebound (TTR) after radiotherapy (RT) and 6 months of androgen deprivation therapy (ADT) impacted the risk of prostate cancer-specific mortality (PCSM) and cardiovascular-specific
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::accfc0eeca76198f10d0873c93fae33d
https://doi.org/10.1002/cncr.31217
https://doi.org/10.1002/cncr.31217
Autor:
Philip W. Kantoff, Katelyn M. Atkins, Eric J. Small, Jing Wu, Ming-Hui Chen, Anthony V. D'Amico, Andrew A. Renshaw, Marian Loffredo
Publikováno v:
Cancer. 124:1383-1390
Background Low testosterone at the time of diagnosis of prostate cancer has been associated with a worse prognosis. Whether this is true and how to define the best treatment approach at the time of first prostate-specific antigen (PSA) failure to the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c9cb0aa32cec7013db84e9c772a8312b
https://doi.org/10.1002/cncr.31204
https://doi.org/10.1002/cncr.31204
Autor:
John Pfail, Philip W. Kantoff, Ming-Hui Chen, Andrew A. Renshaw, Marian Loffredo, Jing Wu, Anthony V. D'Amico, Luke R.G. Pike
Publikováno v:
Urology
4 Background: Whether the time to PSA nadir (TTN) has differential prognostic value in men who reach an undetectable versus detectable PSA nadir remains unknown. Methods: Two-hundred and four men from a prospective randomized controlled trial (RCT) i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78603a85b13b0079d5f9eb50e48bf97e
https://europepmc.org/articles/PMC7829036/
https://europepmc.org/articles/PMC7829036/
Autor:
Anthony Victor D'Amico, Wanling Xie, Elizabeth McMahon, Marian Loffredo, Shana Medeiros, David John Joseph, James William Denham, David S Lamb, Parvesh Kumar, Glenn Bubley, Molly A. Sullivan, Richard Hellwig, Juan Carlos Vera, Rolf Freter, W. Jeffrey Baker, Jeffrey Y.C. Wong, Andrew A. Renshaw, Philip W. Kantoff
Publikováno v:
Journal of Clinical Oncology. 39:5011-5011
5011 Background: For men with unfavorable-risk non-metastatic (M0) prostate cancer (PC) the addition of docetaxel to radical prostatectomy (RP) or radiation therapy (RT) and androgen deprivation therapy (ADT) has been studied in 6 randomized controll
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cfbd834cb21459cb3d595b6bea5415b0
https://doi.org/10.1200/jco.2021.39.15_suppl.5011
https://doi.org/10.1200/jco.2021.39.15_suppl.5011